Delisting Determination,The Nasdaq Stock Market, LLC,
September 26, 2016, Echo Therapeutics, Inc. The Nasdaq
Stock Market, Inc. (the Exchange) has determined to remove
from listing the common stock of Echo Therapeutics, Inc.
(the Company), effective at the opening of the trading
session on October 6, 2016. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rules 5550(b)(1), 5620(a) and 5620(b).
The Company was notified of the Staffs determination on
January 6, 2016.  The Company appealed the determination
to a Hearing Panel. Upon review of the information provided
by the Company, the Panel issued a decision dated
March 9, 2016, granting the Company continued listing
pursuant to an exception that included several milestones
that the Company was required to meet, towards the toal
of regaining compliance with Listing Rules 5550(b)(1),
5620(a) and 5620(b). However, the Company was
unable to meet the exception milestones as required.
On July 8, 2016, the Panel issued a final delisting
determination and notified the Company that trading in the Companys
securities would be suspended on July 12, 2016.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panels Determination to delist the Company
became final on August 22, 2016.